【3 月 3 日,高盛称再鼎医药 2024 年第四季销售表现符合预期!】高盛发表研究报告指出,再鼎医药 2024 年第四季收入按年增长 66%至 1.085 亿美元,符合该行预期的 1.08 亿美元,各项产品收入表现均符合预测。该行认为,公司去年优化商业团队的短期影响已消散,预测 2025 财年艾加莫德收入将达 10 亿元。该行重申 2025 年是再鼎医药发展里程碑年,亏损预期持续收窄,预计今年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.